featured
Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Lancet 2023 Jun 26;[EPub Ahead of Print], WT Garvey, JP Frias, AM Jastreboff, CW le Roux, N Sattar, D Aizenberg, H Mao, S Zhang, NN Ahmad, MC Bunck, I Benabbad, XM ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.